- Home
- HYFM vs SNSE Comparison
HYFM vs SNSE Comparison
Compare HYFM & SNSE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | HYFM | SNSE |
|---|---|---|
| Founded | 1977 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 11.2M | 12.2M |
| IPO Year | 2020 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HYFM | SNSE |
|---|---|---|
| Price | $0.85 | $30.80 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 3 |
| Target Price | N/A | ★ $65.00 |
| AVG Volume (30 Days) | 35.5K | ★ 56.3K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $134,252,000.00 | N/A |
| Revenue This Year | $57.44 | N/A |
| Revenue Next Year | $5.71 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.79 | $0.26 |
| 52 Week High | $4.78 | $36.76 |
Technical Indicators
Market Signals| Indicator | HYFM | SNSE |
|---|---|---|
| Relative Strength Index (RSI) | 41.67 | 51.62 |
| Support Level | $0.86 | $7.94 |
| Resistance Level | $1.33 | $35.94 |
| Average True Range (ATR) | 0.10 | 3.88 |
| MACD | -0.00 | -0.45 |
| Stochastic Oscillator | 27.44 | 53.62 |
Price Performance
Historical ComparisonAbout HYFM Hydrofarm Holdings Group Inc.
Hydrofarm Holdings Group Inc is a distributor and manufacturer of agriculture equipment and supplies. Some of its products includes lighting solutions, growing media (i.e., premium soils and soil alternatives), nutrients, equipment, and supplies sold under proprietary, exclusive/preferred brands, or non-exclusive/distributed brands. The business is organized into two operating segments, the U.S. and Canada.
About SNSE Sensei Biotherapeutics Inc.
Sensei Biotherapeutics Inc is an immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Its TMAb (Tumor Microenvironment Activated Biologics) platform developing selective therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. The company have four investigational product candidates in various stages of development: SNS-101 (VISTA), SNS-102 (VSIG4 ), SNS-103 (ENTPDase/CD39), SNS-201 (VISTAxCD28).